# Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)

Source: https://onco.cc/trials/nct06198907/  
OnCo record `nct06198907` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of golidocitinib and sintilimab in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.

## Summary

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) is a phase 2, interventional study registered as NCT06198907 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 69 participants, started 2024-01 and due to reach its primary completion in 2026-12. Interventions recorded: Golidocitinib; Sintilimab; platinum doublet chemotherapy. Conditions listed: Non-Small-Cell Lung Cancer. Primary outcome: Overall response rate (ORR) (cohort1); Progression-free survival (PFS) (cohort2). Lung eligibility wording from the registry: "Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) , Stage IIIB/IIIC (not suitable for concomitant chemoradiotherapy) or Stage IV according to AJCC 8th". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: JACKPOT33
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06198907
- Phase: 2
- Setting: A Phase 2, Open-label, Single Arm Study to Investigate the Safety and Efficiency of Golidocitinib in Combination With Sintilimab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With PD-L1TPS ≥ 1%)
- Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Enrolled: 69

## Sources

- ClinicalTrials.gov NCT06198907: https://clinicaltrials.gov/study/NCT06198907

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Golidocitinib](https://onco.cc/drugs/golidocitinib/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- companies: [Dizal Pharmaceutical](https://onco.cc/companies/dizal/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06198907.json